Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis. [electronic resource]
- Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics Oct 2017
- 985-998 p. digital
Publication Type: Journal Article; Review
1878-7479
10.1007/s13311-017-0568-1 doi
Child Humans Immunologic Factors--therapeutic use Infusions, Intravenous Multiple Sclerosis--diagnosis Natalizumab--therapeutic use Rituximab--therapeutic use Treatment Outcome